Aviso Wealth Management buys 144 shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Vaseline2 weeks ago

0 5 minutes read

Aviso Wealth Management increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 9.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,596 shares of the medical research company’s stock after acquiring an additional 144 shares during the quarter. Aviso Wealth Management’s holdings in Thermo Fisher Scientific were worth $883,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Capital World Investors boosted its holdings in shares of Thermo Fisher Scientific by 10.0% in the first quarter. Capital World Investors now owns 13,493,852 shares of the medical research company’s stock worth $7,842,762,000 after buying an additional 1,231,059 shares in the last quarter. Swedbank AB bought a new stake in Thermo Fisher Scientific in the first quarter worth $705,636,000. Veritas Asset Management LLP boosted its stake in Thermo Fisher Scientific by 70.1% during the fourth quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company’s stock valued at $898,175,000 after acquiring an additional 697,383 shares during the last quarter. Winslow Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $333,786,000. Finally, Ameriprise Financial Inc. boosted its holdings in Thermo Fisher Scientific by 32.2% in the second quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company’s stock valued at $1,372,157,000 after purchasing an additional 604,895 shares during the period. Institutional investors own 89.23% of the company’s shares.

Thermo Fisher Scientific stock fell 0.8%

NYSE:TMO opened at $614.42 on Friday. The firm has a market cap of $234.71 billion, a P/E ratio of 39.41, a P/E/G ratio of 3.88 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37, and a current ratio of 1.72. Thermo Fisher Scientific Inc. it has a fifty-two week low of $415.60 and a fifty-two week high of $627.88. The firm has a 50 day simple moving average of $606.08 and a two hundred day simple moving average of $581.96.

Want more great investment ideas?

Thermo Fisher Scientific (NYSE:TMO – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. Thermo Fisher Scientific’s revenue was down 1.4% compared to the same quarter last year. During the same period last year, the business earned $5.15 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be given a $0.39 dividend. The ex-dividend date is Friday, September 13. This represents a dividend of $1.56 on an annualized basis and a dividend yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Changes in Analyst Ratings

A number of equities research analysts recently weighed in on TMO shares. Raymond James raised their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. UBS Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. TD Cowen upped their target price on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $767.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, September 20th. Finally, Barclays decreased their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research report on Friday, the 28th June. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $650.41.

Read our latest report on Thermo Fisher Scientific

Insider Trading at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink. In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock worth $14,094,292 over the last three months. 0.34% of shares are currently owned by company insiders.

Thermo Fisher Scientific Company Profile

(Free report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics and laboratory products and biopharmaceutical services in North America, Europe, Asia-Pacific and internationally. The company’s Life Sciences Solutions segment provides reagents, instruments and supplies for biological and medical research, drug and vaccine discovery and production, and infection and disease diagnosis; and solutions include biosciences, genetic sciences and biological manufacturing for the pharmaceutical, biotech, agricultural, clinical, healthcare, academic and government markets.